$4.96
1.43% today
NYSE, Sep 22, 05:23 pm CET
ISIN
US74168J1016
Symbol
PRME

Prime Medicine Stock price

$4.89
+1.65 50.93% 1M
+2.89 144.50% 6M
+1.97 67.47% YTD
+0.98 25.06% 1Y
-12.11 71.24% 3Y
-12.11 71.24% 5Y
-12.11 71.24% 10Y
-12.11 71.24% 20Y
NYSE, Closing price Fri, Sep 19 2025
-0.23 4.49%
ISIN
US74168J1016
Symbol
PRME
Industry

Key metrics

Basic
Market capitalization
$871.4m
Enterprise Value
$769.6m
Net debt
positive
Cash
$101.8m
Shares outstanding
134.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
175.7 | 104.5
EV/Sales
155.2 | 92.3
EV/FCF
negative
P/B
14.3
Financial Health
Equity Ratio
51.5%
Return on Equity
-127.9%
ROCE
-83.4%
ROIC
-129.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.0m | $8.3m
EBITDA
$-197.4m | $-172.4m
EBIT
$-204.2m | $-187.1m
Net Income
$-199.3m | $-163.9m
Free Cash Flow
$-107.0m
Growth (TTM | estimate)
Revenue
740.7% | 179.9%
EBITDA
9.5% | 12.2%
EBIT
8.6% | 7.6%
Net Income
8.4% | 16.3%
Free Cash Flow
47.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,978.7% | -2,067.3%
EBIT
-4,116.6%
Net
-4,016.8% | -1,965.2%
Free Cash Flow
-2,156.8%
More
EPS
$-1.5
FCF per Share
$-0.8
Short interest
17.8%
Employees
214
Rev per Employee
$10.0k
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Prime Medicine forecast:

13x Buy
72%
5x Hold
28%

Analyst Opinions

18 Analysts have issued a Prime Medicine forecast:

Buy
72%
Hold
28%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.96 4.96
741% 741%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
12% 12%
1,065%
- Research and Development Expense 156 156
4% 4%
3,153%
-197 -197
10% 10%
-3,979%
- Depreciation and Amortization 6.84 6.84
28% 28%
138%
EBIT (Operating Income) EBIT -204 -204
9% 9%
-4,117%
Net Profit -199 -199
8% 8%
-4,018%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Neutral
Seeking Alpha
14 days ago
Prime Medicine, Inc. (NASDAQ:PRME ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Okay. Well, thanks, everybody, for joining us.
Neutral
Seeking Alpha
20 days ago
Prime Medicine, Inc. (NASDAQ:PRME ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President It's my pleasure to be hosting Prime Medicine for a fireside chat. I'm joined by Allan Reine, CEO of Prime as...
Neutral
GlobeNewsWire
27 days ago
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at ...
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 214
Founded 2019
Website primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today